# Janssen Vaccines & Prevention B.V.

Canonical: https://abierto.us/vendors/janssen-vaccines-and-prevention-b-v-vre2eknjtjj4

- UEI: VRE2EKNJTJJ4
- CAGE: H1N64
- Parent: Johnson & Johnson
- Location: Leiden, NLD
- Awards in window: 3 (7 transactions), -$620,809 obligated, March 7, 2024 to October 2, 2025

## Awarding agencies

- National Institutes of Health: 1 awards, $0
- Office of Assistant Secretary for Preparedness and Response: 2 awards, -$620,809

## Industries

- 541712 Professional, Scientific, and Technical Services: $0
- 541711 Professional, Scientific, and Technical Services: -$620,809

## Competition

- Full and Open Competition: 3 awards

## Largest awards

- HHSN272200800056C (definitive contract): $0, National Institutes of Health Niaid. Advanced Development of Multivalent Filovirus (Ebola and Marburg) Hemorrhagic Fever Vaccines. https://www.usaspending.gov/award/CONT_AWD_HHSN272200800056C_7529_-NONE-_-NONE-/
- HHSO100201700013C (definitive contract): $0, Barda - Aspr / Daappo / Barda DCMA. The Purpose of This Modification Is to Update Key Personnel and Change the Submission of the Monthly Report to Quarterly.. https://www.usaspending.gov/award/CONT_AWD_HHSO100201700013C_7505_-NONE-_-NONE-/
- HHSO100201500008C (definitive contract): -$620,809, Barda - Aspr / Daappo / Barda DCMA. De-Obligate FY24 Canceling Funds.. https://www.usaspending.gov/award/CONT_AWD_HHSO100201500008C_7505_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/janssen-vaccines-and-prevention-b-v-vre2eknjtjj4.